Review: regular inhaled short acting β2 agonists improve lung function in stable chronic obstructive pulmonary disease
Q Is regular treatment with inhaled short acting β2 agonists (ISABAs) effective for stable chronic obstructive pulmonary disease (COPD)?
Cochrane Collaboration trials register up to and including May 2002 and reference lists of review articles and retrieved studies.
Study selection and assessment:
randomised, placebo controlled trials of ISABAs given to patients with stable COPD for ⩾7 days. Individual study quality was assessed on the basis of allocation concealment.
forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEFR), breathlessness (visual analogue scale), treatment failure, and patient preference.
13 crossover trials met the …